Valuation: Epigenomics AG

Market Cap 789K 903K 730K 674K 1.27M 86.75M 1.29M 8.7M 3.41M 42.48M 3.39M 3.32M 146M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.76M 13.45M 10.87M 10.04M 18.91M 1.29B 19.25M 130M 50.85M 633M 50.53M 49.41M 2.18B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
1 day+3.45%
1 week-18.18%
Current month+3.45%
1 month-4.26%
3 months-2.17%
1 week 0.87
Extreme 0.87
1.1
1 month 0.87
Extreme 0.87
1.4
Current year 0.84
Extreme 0.84
1.55
1 year 0.84
Extreme 0.84
1.59
3 years 0.5
Extreme 0.5
4.2
5 years 0.5
Extreme 0.5
25.88
10 years 0.5
Extreme 0.5
1,187.36
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 2024-01-31
Director TitleAgeSince
Chairman 58 2023-02-28
Director/Board Member 55 2020-05-31
Director/Board Member 56 2024-02-04
Date Insider Type Main position Quantity % Market Cap.
22-12-28Buy

Chief Financial Officer

2,000 0.0122%
21-09-06Sell

Director

7,790 0.0637%
21-01-31Buy

Chairman

6,355 0.1079%
Change 5-day change 1-year change 3-year change Capi.($)
+3.45%-18.18%+5.88%-76.16% 903K
-1.50%+0.82%+112.46%+96.53% 4.52B
+1.95%+2.93%+85.54%+198.88% 3.43B
-1.34%+4.27%-26.93%-38.96% 2.05B
-2.72%-9.66%+95.52%-49.36% 1.75B
+0.59%+2.19%+44.51%+196.11% 1.49B
+2.36%+9.97%+143.82%-49.10% 960M
-2.81%-5.63%-14.53%+32.93% 846M
-5.41%-4.42%+6.06% - 475M
+2.71%-0.89%-37.20%-17.18% 485M
Average -0.27%-0.91%+41.51%+32.63% 1.6B
Weighted average by Cap. -0.51%+0.09%+68.15%+78.36%

Financials

2024 2025
Net sales - 24K 27.46K 22.19K 20.5K 38.6K 2.64M 39.3K 265K 104K 1.29M 103K 101K 4.45M
Net income -3.35M -3.84M -3.1M -2.86M -5.39M -368M -5.49M -36.95M -14.5M -180M -14.41M -14.09M -621M -314K -359K -290K -268K -505K -34.51M -514K -3.46M -1.36M -16.9M -1.35M -1.32M -58.19M
Net Debt 10.46M 11.96M 9.66M 8.93M 16.82M 1.15B 17.12M 115M 45.22M 563M 44.94M 43.94M 1.94B 10.97M 12.55M 10.14M 9.37M 17.64M 1.21B 17.96M 121M 47.44M 590M 47.14M 46.1M 2.03B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
3
Date Price Change Volume
26-07-14 €0.9000 +3.45% 200
26-07-13 €0.8700 0.00% 590
26-07-10 €0.8700 0.00% 4
26-07-09 €0.8700 -0.57% 0
26-07-08 €0.8750 -20.45% 500

Annual profits - Rate of surprise